These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 16285718)

  • 1. Isolation and characterization of the B-cell marker CD20.
    Ernst JA; Li H; Kim HS; Nakamura GR; Yansura DG; Vandlen RL
    Biochemistry; 2005 Nov; 44(46):15150-8. PubMed ID: 16285718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystal structure of chimeric antibody C2H7 Fab in complex with a CD20 peptide.
    Du J; Wang H; Zhong C; Peng B; Zhang M; Li B; Hou S; Guo Y; Ding J
    Mol Immunol; 2008 May; 45(10):2861-8. PubMed ID: 18346788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab).
    Nishida M; Usuda S; Okabe M; Miyakoda H; Komatsu M; Hanaoka H; Teshigawara K; Niwa O
    Int J Oncol; 2007 Jul; 31(1):29-40. PubMed ID: 17549402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.
    Davis TA; Czerwinski DK; Levy R
    Clin Cancer Res; 1999 Mar; 5(3):611-5. PubMed ID: 10100713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [One amino acid mutation in an anti-CD20 antibody fragment that affects the yield bacterial secretion and the affinity].
    Liu YX; Xiong DS; Fan DM; Shao XF; Xu YF; Zhu ZP; Yang CZ
    Sheng Wu Gong Cheng Xue Bao; 2003 May; 19(3):272-6. PubMed ID: 15969005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A CD20 tandem-epitope immunogen elicits antibody in mice that binds murine cell surface CD20 and depletes splenic B cells in vivo.
    Oscherwitz J; Gribbin TE; Cease KB
    Mol Immunol; 2010 Apr; 47(7-8):1484-91. PubMed ID: 20189250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholesterol depletion inhibits src family kinase-dependent calcium mobilization and apoptosis induced by rituximab crosslinking.
    Unruh TL; Li H; Mutch CM; Shariat N; Grigoriou L; Sanyal R; Brown CB; Deans JP
    Immunology; 2005 Oct; 116(2):223-32. PubMed ID: 16162271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis.
    Janas E; Priest R; Wilde JI; White JH; Malhotra R
    Clin Exp Immunol; 2005 Mar; 139(3):439-46. PubMed ID: 15730389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-CD20 treatments and the lymphocyte membrane: pathology for therapy.
    Borisch B; Semac I; Soltermann A; Palomba C; Hoessli DC
    Verh Dtsch Ges Pathol; 2001; 85():161-6. PubMed ID: 11894393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a peptide ELISA for the detection of rituximab in serum.
    Blasco H; Lalmanach G; Godat E; Maurel MC; Canepa S; Belghazi M; Paintaud G; Degenne D; Chatelut E; Cartron G; Le Guellec C
    J Immunol Methods; 2007 Aug; 325(1-2):127-39. PubMed ID: 17651747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of human B-cell lymphoma by an anti-CD20 antibody and its chimeric F(ab')2 fragment via induction of apoptosis.
    Liu Y; Zheng M; Lai Z; Xiong D; Fan D; Xu Y; Peng H; Shao X; Xu Y; Yang M; Wang J; Liu H; Xie Y; Yang C; Zhu Z
    Cancer Lett; 2004 Mar; 205(2):143-53. PubMed ID: 15036646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
    Flavell DJ; Warnes SL; Bryson CJ; Field SA; Noss AL; Packham G; Flavell SU
    Br J Haematol; 2006 Jul; 134(2):157-70. PubMed ID: 16771848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concepts in radiotherapy and immunotherapy: anti-CD20 mechanisms of action and targets.
    Maloney DG
    Semin Oncol; 2005 Feb; 32(1 Suppl 1):S19-26. PubMed ID: 15786022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD20 as a target for therapeutic type I and II monoclonal antibodies.
    Beers SA; Chan CH; French RR; Cragg MS; Glennie MJ
    Semin Hematol; 2010 Apr; 47(2):107-14. PubMed ID: 20350657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mimotope vaccination for epitope-specific induction of anti-CD20 antibodies.
    Li M; Yan Z; Han W; Zhang Y
    Cell Immunol; 2006 Feb; 239(2):136-43. PubMed ID: 16814270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes.
    Golay J; Cittera E; Di Gaetano N; Manganini M; Mosca M; Nebuloni M; van Rooijen N; Vago L; Introna M
    Haematologica; 2006 Feb; 91(2):176-83. PubMed ID: 16461301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.
    Smith MR
    Oncogene; 2003 Oct; 22(47):7359-68. PubMed ID: 14576843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties.
    Carnahan J; Wang P; Kendall R; Chen C; Hu S; Boone T; Juan T; Talvenheimo J; Montestruque S; Sun J; Elliott G; Thomas J; Ferbas J; Kern B; Briddell R; Leonard JP; Cesano A
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3982S-90S. PubMed ID: 14506197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD20 expression in normal canine B cells and in canine non-Hodgkin lymphoma.
    Jubala CM; Wojcieszyn JW; Valli VE; Getzy DM; Fosmire SP; Coffey D; Bellgrau D; Modiano JF
    Vet Pathol; 2005 Jul; 42(4):468-76. PubMed ID: 16006606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.